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ABSTRACT
Objectives: To identify metabolic markers that can
classify patients with osteoarthritis (OA) into subgroups.
Design: A case-only study design was utilised.
Participants: Patients were recruited from those who
underwent total knee or hip replacement surgery due to
primary OA between November 2011 and December
2013 in St. Clare’s Mercy Hospital and Health Science
Centre General Hospital in St. John’s, capital of
Newfoundland and Labrador (NL), Canada. 38 men and
42 women were included in the study. The mean age was
65.2±8.7 years.
Outcome measures: Synovial fluid samples were
collected at the time of their joint surgeries. Metabolic
profiling was performed on the synovial fluid samples by
the targeted metabolomics approach, and various
analytic methods were utilised to identify metabolic
markers for classifying subgroups of patients with OA.
Potential confounders such as age, sex, body mass index
(BMI) and comorbidities were considered in the analysis.
Results: Two distinct patient groups, A and B, were
clearly identified in the 80 patients with OA. Patients in
group A had a significantly higher concentration on 37 of
39 acylcarnitines, but the free carnitine was significantly
lower in their synovial fluids than in those of patients in
group B. The latter group was further subdivided into two
subgroups, that is, B1 and B2. The corresponding
metabolites that contributed to the grouping were
86 metabolites including 75 glycerophospholipids
(6 lysophosphatidylcholines, 69 phosphatidylcholines),
9 sphingolipids, 1 biogenic amine and 1 acylcarnitine.
The grouping was not associated with any known
confounders including age, sex, BMI and comorbidities.
The possible biological processes involved in these
clusters are carnitine, lipid and collagen metabolism,
respectively.
Conclusions: The study demonstrated that OA consists
of metabolically distinct subgroups. Identification of
these distinct subgroups will help to unravel the
pathogenesis and develop targeted therapies for OA.
INTRODUCTION
Osteoarthritis (OA) is a heterogeneous
disease with various pathogenic factors and
consists of different phenotypes which
continually evolve, eventually leading to
common clinical and radiographic manifesta-
tions.1 Various classifications have been pro-
posed depending on the main underlying
pathophysiological mechanisms,2 clinically
relevant patient characteristics,3 stage of
disease,4 involved joints5 6 and degree of
inflammation.7 However, most patients could
not fit easily into these proposed OA sub-
groups2 due to the complexity of the influen-
cing factors.
Recent studies have implied that OA is a
metabolic disease linked to several compo-
nents of the metabolic syndrome, such as
hypertension, type-2 diabetes and dyslipide-
mia.8–10 Metabolites represent intermediate
and end products of various cellular pro-
cesses, whose levels can be regarded as a con-
sequence of biological systems response to
genotypic and environmental influences.
Synovial fluid (SF) is an ultrafiltrate of
plasma that also contains locally synthesised
factors. Altered composition or concentra-
tions of SF components are directly linked to
OA.11 Using a metabolomics approach, we
identified branched-chain amino acid to his-
tidine ratio as a novel metabolic biomarker
Strengths and limitations of this study
▪ The strength of the study is the use of synovial
fluid samples rather than plasma or urine
samples. The metabolic profiling in synovial fluid
reflects directly what is happening in a joint and
yields the most accurate, real-time and
joint-specific metabolic profile that is relevant to
osteoarthritis (OA).
▪ OA is a heterogeneous disease. This is the first
study that demonstrated that OA consists of at
least three metabolically distinct subgroups,
which are likely due to the differences in carni-
tine, lipid and collagen metabolism.
▪ The study was limited to only patients with
OA, and we did not have synovial fluid samples
from healthy people. A study with control syn-
ovial fluid samples is needed to confirm the
findings.
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for knee OA.12 13 Other than biomarker identification,
classification for a heterogeneous condition such as OA
will require a reliable analytical method with good sensi-
tivity and accuracy because the variation of the metabol-
ite concentrations between phenotypes for a
heterogeneous disease may be much narrower than that
between people with and without the disease.
The Biocrates AbsoluteIDQ p180 kit is a commercially
available product for targeted metabolomics which can
simultaneously identify and quantify 186 metabolites
from 5 different compound classes. The assay is per-
formed using a combined ultra performance liquid
chromatography (UPLC) and mass spectrometry-based
flow injection analysis (FIA) method which has proven
to be in conformance with the Food and Drug
Administration (FDA) Guideline “Guidance for Industry
—Bioanalytical Method Validation”.14 Compared with
untargeted screening, the multiple reaction monitoring
(MRM) mode was adopted in this method which can
offer better sensitivity and quantitative accuracy for ana-
lysis. Our previous study12 has demonstrated it to be a
reliable and sensitive method for metabolite detection.
In the present study, we used the p180 kit to identify
metabolic markers in SFs that can be used to classify
patients with OA into distinct subgroups.
PATIENTS AND METHODS
Patients
The present study was part of the Newfoundland
Osteoarthritis Study (NFOAS) that was initiated in 2011
and aimed at identifying novel genetic, epigenetic and
biochemical markers for OA.15 Patients with OA were
recruited from those who underwent total knee or hip
replacement surgery due to primary OA between
November 2011 and December 2013 in St. Clare’s Mercy
Hospital and Health Science Centre General Hospital in
St. John’s, the capital city of Newfoundland and
Labrador (NL), Canada. The response rate was 90%.
OA diagnosis was performed based on the American
Rheumatology College’s criteria and the judgement of
the attending orthopaedic surgeon.
Demographic and comorbidities
Demographic and medical information was collected by
a self-administered general questionnaire with the assist-
ance of research staff if necessary. Age was calculated at
the time of surgery. Comorbidities including eight
metabolic-related diseases (heart disease, hypertension,
high blood pressure in pregnancy, high cholesterol, dia-
betes, stroke, gout and osteoporosis) were confirmed by
reviewing the electronic hospital records, which contain
relevant clinical, laboratory and radiographic informa-
tion. Height and weight measurements were obtained
from the patient’s hospital medical records. BMI was cal-
culated as weight in kilograms divided by the squared
height in metres.
Metabolic profiling
SFs were collected during the joint surgeries. Prior to
knee arthrotomy/hip capulotomy, a syringe was inserted
into the suprapatellar pouch of the knee/hip along the
femoral neck, and 2–4 mL of the SF samples was aspi-
rated. The samples were then put in vials and stored in
liquid nitrogen until analysis. Metabolic profiling was
performed by using the Waters XEVO TQ MS system
(Waters Limited, Mississauga, Ontario, Canada) coupled
with the Biocrates AbsoluteIDQ p180 kit, which mea-
sures 186 metabolites including 90 glycerophospholi-
pids, 40 acylcarnitines (1 free carnitine), 21 amino acids,
19 biogenic amines, 15 sphingolipids and 1 hexose
(>90% is glucose). The details of these 186 metabolites
are listed in online supplementary table S1. The meta-
bolic profiling method using this kit was described
previously.12
Statistical methods
Data analyses encompassed hundreds of variables that
are highly correlated. Dimension reduction was per-
formed by multivariate methods that not only sought to
capture changes of single metabolites between different
groups, but also to utilise the dependency structures
between the individual molecules. Principal component
analysis (PCA), cluster analysis and partial least squares
(PLS) regression, which are the most prominent multi-
variate analysis techniques applied in the research of
metabolomics,16 were used in the analysis.
PCA is a statistical procedure that uses an orthogonal
transformation to convert a set of observations of pos-
sibly correlated variables into a set of principal compo-
nents. The first principal component has the largest
possible variance, and each succeeding component in
turn has the highest variance possible.17 Hierarchical
cluster analysis (HCA) is also an unsupervised multivari-
ate technique and was used to18 provide a visual descrip-
tion of the evolution of the clusters. Identification of the
characteristic metabolites with significance between clus-
ters was performed using the PLS-Discriminant Analysis
(PLS-DA) method implemented in SIMCA-P 11.5
(Umetrics AB, Umea, Sweden) software. In PLS-DA, the
R2X, R2Y and Q2 (cum) parameters were used for the
model evaluation. R2X is the percentage of all response
variables explained by the model. R2Y is the percentage
of all observation or sample variables explained by the
model. Q2 is the percentage of all observation or
sample variables predicted by the model. The import-
ance of each metabolite in the PLS-DA was evaluated by
variable importance in the projection (VIP) score. The
VIP score positively reflects the metabolite’s influence
on the classification, and metabolites with a score
greater than 1 were considered important in this study.
Additionally, the Kruskal-Wallis test was executed using
Multi Experiment View (V.4.9) software to determine
the significant metabolites. The significance level was
defined as p<0.01. A heatmap was made using Multi
Experiment View (V.4.9) software to present a detailed
2 Zhang W, et al. BMJ Open 2014;4:e006286. doi:10.1136/bmjopen-2014-006286
Open Access
group.bmj.com on March 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
description for each group. Discriminatory metabolites
with these parameters are identified.
The above analyses were performed on concentrations
obtained from the Absolute IDQ kit. Before analysis, raw
data were filtered by the presence of metabolites in at
least 80% of patients and all data were mean-centred
and standardised.
RESULTS
A total of 38 men and 42 women were included in the
study. The mean age was 65.2±8.7 years, and the mean
BMI was 33.3±6.9 kg/m2. We had data on eight
metabolic-related diseases including hypertension, dysli-
pidemia and diabetes that were previously reported to
be associated with OA.10 The detailed descriptive statis-
tics are presented in table 1.
Over 90% of the potential metabolites (168/186) were
successfully determined in each sample. These included
40 acylcarnitines (1 free carnitine), 20 amino acids,
9 biogenic amines, 87 glycerophospholipids, 11 sphingo-
lipids and 1 hexose (>90% is glucose). Since there were
vast differences in the absolute concentrations among
different metabolites, we standardised the concentration
by using the Z-score for comparability between different
metabolites for their biological relevance and used them
in subsequent analyses.
Figure 1 presents the PCA results. Eighty patients with
OA were clearly clustered into two distinct groups, that
is, cluster A and cluster B (including several sub-
assembling groups). Cluster A including 11 patients
mainly assembled in the first quadrant, while cluster B
consists of 69 patients scattered along the X-axis. From
the loading values, PC ae C40:1, PC ae C40:5, PC ae
C36:1, PC ae C40:4 and PC ae C40:3 were the major
contributors for component 1, whereas C12, C6:1,
C3-OH, C3-DC (C4-OH), C3:1, C14:1 and C14 were the
main contributors for component 2.
Using the HCA method, the patients of cluster B can
be further classified into two subgroups, B1 and B2. It
also appeared that group B1 could be divided into B1-1,
B1-2-1 and B1-2-2 groups, and B2 could be subdivided
into B2-1 and B2-2 groups, respectively (figure 2).
Identification of the metabolites with the most signifi-
cantly different concentrations between groups was per-
formed using the PLS-DA method. Data obtained from
cluster A and cluster B were first used to construct a
PLS-DA model, which showed the performance statistics
of R2X=0.603, R2Y=0.983 and with a high prediction
parameter Q2 (cum) of 0.98. The discriminant analysis
showed that the concentrations of 37 acylcarnitines in
cluster A were significantly higher than that in cluster B
(13.5±14.0 fold for 34 of 37, 309±261 fold for 3 of 37,
all p<0.01), while C0 (free carnitine, L-3-hydroxy-4-
aminobutyrobetaine) and C2 (acetylcarnitine) were sig-
nificantly lower in Cluster A than that in cluster B (2.7
fold for C2, 3.1 fold for C0, all p<0.01; figure 3). When
the ratios of acylcarnitines to C0 was calculated, cluster
A had far greater ratios than that of cluster B (p<0.01).
However, the total carnitine (acyl+free) level was not
Table 1 Descriptive statistics of the study population*
Clusters
A
(n=11)
B (n=69)
B1
(n=48)
B2
(n=21)
Age (years) 67.2±5.8 64.8±7.8 65.3±11.8
Sex ratio (female %) 55 52 52
BMI (kg/m2) 35.9±5.7 34.2±7.3 29.6±5.3
Disease
Heart disease (%) 0 8.3 9.5
Hypertension (%) 27.2 47.9 33.3
High blood pressure in
pregnancy (%)
0 4.2 4.8
High cholesterol (%) 27.2 39.6 28.6
Diabetes (%) 18.2 12.5 23.8
Stroke (%) 9.1 4.2 0
Gout (%) 0 10.4 9.5
Osteoporosis (%) 9.1 12.5 0
*Data are presented as mean±SD unless indicated.
BMI, body mass index.
Figure 1 The result of the
principal component analysis.
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statistically significant between group A and group B
(p=0.75).
Data were obtained from clusters B1 and B2 to con-
struct a PLS-DA model with parameters: R2X=0.546,
R2Y=0.854 and Q2 (cum) of 0.98. The discriminant ana-
lysis between clusters B1 and B2 was executed. A total of
86 metabolites including 75 glycerophospholipids (6 lyso-
phosphatidylcholines, 69 phosphatidylcholines), 9 sphin-
golipids, 1 biogenic amine and 1 acylcarnitine were
found to be significantly higher in cluster B2 than in
cluster B1 by 1.58 fold, 1.83 fold, 1.72 fold, 1.19 fold and
1.82 fold, respectively (all p<0.01). However, there are
two acylcarnitines, C3 and C5, with a slightly lower con-
centration in B2 than in B1.
Specific metabolites that were distinct between B1-1,
B1-2-1, B1-2-2, B2-1 and B2-2 were obtained by the
PLS-DA method with VIP>1 and p<0.01, and the results
are shown in figure 4 and online supplementary table
S2. The significant metabolites include 14 amino acids,
24 glycerophospholipids, 12 acylcarnitines and 1
sphingolipid, in which proline had the biggest VIP
value. Group B1-2-2 samples have a higher concentra-
tion in 12 amino acids and 1 biogenic amine than in the
other four groups. Group B2-1 samples have the highest
level of two amino acids (glutamate and ornithine) and
all glycerophospholipids except two lyso-PC types
(lyso-PC 16:0 and 16:1). On the whole, group B1-2-1 and
group B2-2 have a compromised concentration in all sig-
nificant metabolites and cluster B1-1 has the lowest con-
centration in all metabolites.
We explored whether the groupings were associated
with any of the potential covariates. For groups A and B,
the mean ages were 67.2±5.8 years and 64.9±9 years,
respectively, but the difference was not statistically signifi-
cant (p=0.42). Women made up 55% of group A and 52%
of group B. The average BMI in group A was 35.9±5.7 kg/
m2, which was higher than that in group B (32.8±7.0 kg/
m2), but the difference was not statistically significant
(p=0.17). We had data on eight metabolic-related diseases
(heart disease, hypertension, high blood pressure in preg-
nancy, high cholesterol, diabetes, stroke, gout and osteo-
porosis) on all the study participants. The more prevalent
diseases in these patients with OA were hypertension
(41.3%), high cholesterol (35%) and diabetes (16.3%).
Although group A had a tendency of low prevalence of
these metabolic-related diseases than group B, the differ-
ences were not statistically significant (all p>0.05).
For the groups B1 and B2, there was no significant dif-
ference in age and sex between groups B1 and B2, but
BMI in group B1 was higher than that in group B2 (34.2
±7.2 vs 29.6±5.3, 0.01<p<0.05).
DISCUSSION
To the best of our knowledge, this is the first study that
used the metabolomics approach to classify patients with
Figure 2 Hierarchical clustering analysis for group B
(69 patients).
Figure 3 Heatmaps of
significant metabolites for the
separation of groups A and B.
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OA into different distinct subgroups. The strength of the
study is the use of SF samples rather than plasma or urine
samples. Our unpublished data suggested that the metab-
olite correlation between plasma and SF was only modest
(an average correlation coefficient of 0.22). Metabolic pro-
filing in SF reflects directly what is happening in a joint
and yields the most accurate, real-time and joint-specific
metabolic profile that is relevant to OA.19
On the basis of metabolic profiling of the SFs, we clas-
sified 80 patients with OA into two large groups, that is,
group A and group B. This is largely due to the differ-
ence in concentrations of acylcarnitines. Fasting might
be a factor explaining the difference; however, all
patients fasted on their surgery dates. When using the
ratio of the concentrations of acylcarnitines to free carni-
tine (C0), group A exclusively had greater ratios than
did group B, indicating that two distinguished OA sub-
phenotypes may be related to the carnitine metabolism
pathway.
In humans, the major sources of camitine (C0) are de
novo synthesis and the diet. In the process of synthesis
of carnitine, glycine can be released as a by-product;20
however, there were no significant differences between
both groups in the concentration of this metabolite.
Carnitine acyltransferases are responsible for the pro-
duction of acylcarnitines and the value of the acylcarni-
tines/carnitine ratio can reflect its activity.20 21 In the
present study, the ratio of acylcarnitine to carnitine in
group A is significantly higher than that of cluster B,
which may indicate that the activity of acyltransferases is
higher in patients of group A than group B. Carnitine
and its acyl esters acylcarnitines are essential compounds
for the metabolism of fatty acids. Carnitine can assist in
the transport and metabolism of fatty acyl-CoA from the
cytosol to the mitochondrial matrix, where the enzymes
of β-oxidation are located and fatty acids are oxidised as
a major source of energy. Inside the mitochondria, car-
nitine and acyl-CoA are regenerated, and the latter is
catabolised in two-carbons units by β-oxidation, with pro-
duction of acetyl-CoA in normal circumstances. Then
the acetyl groups are converted to acetylcarnitine via the
action of carnitine acetyltransferase for transport out of
the mitochondria. In the patients of group A, both car-
nitine (C0) and acetylcarnitine (C2) are significantly
lower than in patients in group B; however, the concen-
trations of other acylcarnitines are all significantly
higher in group A than that in group B. This suggests
that the activity of carnitine acetyltransferase is signifi-
cantly lower in group B and there are differences in fatty
acid metabolism between these two groups. Elevated
acylcarnitine levels have been detected in obesity,22
type-2 diabetes,23 cardiovascular disease24 and
encephalopathy.25
Group B can be classified into group B1 and B2 based
on the HCA. The significant metabolites that contribute
to these subgroups are mainly glycerophospholipids,
sphingolipids and amino acids
The physiological significance regarding OA for these
kinds of metabolites has been previously studied.
Glycerophospholipids form the essential lipid bilayer of
all biological membranes and are intimately involved in
signal transduction, regulation of membrane trafficking
and many other membrane-related phenomena.26 27
Studies by Hills28 indicated that alterations in phospho-
lipid composition and concentrations are associated with
the development of OA. Kosinska et al29 also found that
in comparison with control SF, the levels of glyceropho-
spholipids (Five phosphatidylglycerol and two lysopho-
sphatidylglycerol species) were all elevated in late OA by
3.6-fold. Our results are consistent with their findings.
Figure 4 Heatmaps of
significant metabolites for the
separation of cluster B1-1.
B1-2-1, B1-2-2, B2-1 and B2-2,
p<0.01.
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The concentrations of 24 glycerophospholipids in
patients of group B2 were all significantly higher than
those in patients of group B1, especially for the PC types.
Sphingolipids are a class of lipids that include cera-
mide species, sphingomyelins (SMs) and more complex
glycosphingolipids, which are an important part of SF.
Sphingolipids are structural components of plasma
membranes and bioactive molecules that have significant
functions in proliferation and growth as well as differen-
tiation, cellular signal transduction and apoptosis in
many mammalian cells, for instance, fibroblast-like syno-
viocytes and neural cells.30–33 Studies by Marta et al29
suggest that SM species had risen approximately twofold
in SF from early OA to late OA. In our study, the con-
centration of nine significant sphingolipids (6 SM, 3 SM
(OH)) in group B2 was significantly higher than that in
group B1 by about 1.7 fold.
In metabolic disorders, the knowledge of the concen-
tration of one amino acid or related group of amino
acids is essential for correct diagnosis. For example, the
cellular energy metabolism accessed by amino acids pro-
filing can be used for in-depth analysis of chronic
fatigue syndrome.34 The branched-chain amino acids
(BCAA), valine, isoleucine and leucine, are essential
amino acids, accounting for 35% of the essential amino
acids in muscle proteins. On the basis of our previous
studies, we believe it could be possible that an increased
concentration of the BCAA leads to an increased pro-
duction of cytokines, which then leads to an increased
rate of joint collagen degradation. An increased level of
cytokines has been associated with OA.12 35 In the
current study, some amino acids, including these three
BCAA amino acids, were elevated in group B1-2-2, which
could indicate that the patients with OA in this group
were more likely concerned with collagen degradation.
The proline, hydroxyproline and hydroxylysine levels are
important indicators of connective tissue status.36 There
were reports that proline incorporation into osteoarth-
ritic cartilage was increased 4-fold as compared to
normal cartilage.37
Age, sex, BMI and comorbidities could be potential
confounders. However, we did not find the grouping
based on metabolic profiling in the present study to be
associated with any of these potential confounders.
Nevertheless, patients in group B tend to have a higher
prevalence of hypertension than patients in group
A. Liu et al,38 using metabolomics analysis, showed sig-
nificantly increased serum fatty acid levels in hyperten-
sion patients, which is consisted with our results.
There are some caveats. First, this is a case-only study
and we do not have SF samples from healthy people.
Although the metabolic map has presented a clear diver-
sity character for patients with OA, metabolite concen-
trations in healthy people would provide a normal range
so that we could distinguish which group has normal
concentrations. Second, we do not have dietary and
drug used information on the study participants, which
might have an influence on metabolite concentrations,
but the Newfoundland population is an isolated popula-
tion characterised by relative environmental homogen-
eity and metabolite concentrations in SFs is less
influenced by dietary intake. Third, we used a targeted
metabolomics approach; thus, we might have missed
important OA-associated metabolites which we were
unable to measure. Lastly, our sample size was modest
and a follow-up study with a large sample size is required
to verify the findings.
CONCLUSION
This is the first study using a metabolomics approach to
classify patients with OA and demonstrated that OA con-
sists of metabolically distinct subgroups. While the find-
ings need to be confirmed, the identification of these
distinct subgroups will help to unravel the pathogenesis
and develop targeted therapies for OA.
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